S'abonner

Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study - 22/12/17

Doi : 10.1016/S1473-3099(17)30474-7 
Nathan C Bahr, MD a, b, Edwin Nuwagira, MBChB c, Emily E Evans, BS c, Fiona V Cresswell, MBChB d, e, Philip V Bystrom, BA a, Adolf Byamukama, BMLS c, Sarah C Bridge, BS a, c, Ananta S Bangdiwala, MS a, David B Meya, PhD a, d, Claudia M Denkinger, MD f, Conrad Muzoora, MMed c, David R Boulware, ProfMD a,
on behalf of the

ASTRO-CM Trial Team

Darlisha A Williams, Kabanda Taseera, Dan Nyehangane, Mugisha Ivan, Patrick Orikiriza, Joshua Rhein, Kathy Huppler Hullsiek, Abdu Musubire, Katelyn Pastick, Pamela Nabeta, James Mwesigye, Radha Rajasingham

a Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA 
b Division of Infectious Diseases, Department of Medicine, University of Kansas, Kansas City, MO, USA 
c Mbarara University of Science and Technology, Mbarara, Uganda 
d Infectious Disease Institute, Makerere University, Kampala, Uganda 
e Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK 
f Foundation for Innovative New Diagnostics, Geneva, Switzerland 

* Correspondence to: Prof David Boulware, University of Minnesota, Minneapolis, MN 55455, USA Correspondence to: Prof David Boulware University of Minnesota Minneapolis MN 55455 USA

Summary

Background

WHO recommends Xpert MTB/RIF as initial diagnostic testing for tuberculous meningitis. However, diagnosis remains difficult, with Xpert sensitivity of about 50–70% and culture sensitivity of about 60%. We evaluated the diagnostic performance of the new Xpert MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis.

Methods

We prospectively obtained diagnostic cerebrospinal fluid (CSF) specimens during screening for a trial on the treatment of HIV-associated cryptococcal meningitis in Mbarara, Uganda. HIV-infected adults with suspected meningitis (eg, headache, nuchal rigidity, altered mental status) were screened consecutively at Mbarara Regional Referral Hospital. We centrifuged CSF, resuspended the pellet in 2 mL of CSF, and tested 0·5 mL with mycobacteria growth indicator tube culture, 1 mL with Xpert, and cryopreserved 0·5 mL, later tested with Xpert Ultra. We assessed diagnostic performance against uniform clinical case definition or a composite reference standard of any positive CSF tuberculous test.

Findings

From Feb 27, 2015, to Nov 7, 2016, we prospectively evaluated 129 HIV-infected adults with suspected meningitis for tuberculosis. 23 participants were classified as probable or definite tuberculous meningitis by uniform case definition, excluding Xpert Ultra results. Xpert Ultra sensitivity was 70% (95% CI 47–87; 16 of 23 cases) for probable or definite tuberculous meningitis compared with 43% (23–66; 10/23) for Xpert and 43% (23–66; 10/23) for culture. With composite standard, we detected tuberculous meningitis in 22 (17%) of 129 participants. Xpert Ultra had 95% sensitivity (95% CI 77–99; 21 of 22 cases) for tuberculous meningitis, which was higher than either Xpert (45% [24–68]; 10/22; p=0·0010) or culture (45% [24–68]; 10/22; p=0·0034). Of 21 participants positive by Xpert Ultra, 13 were positive by culture, Xpert, or both, and eight were only positive by Xpert Ultra. Of those eight, three were categorised as probable tuberculous meningitis, three as possible tuberculous meningitis, and two as not tuberculous meningitis. Testing 6 mL or more of CSF was associated with more frequent detection of tuberculosis than with less than 6 mL (26% vs 7%; p=0·014).

Interpretation

Xpert Ultra detected significantly more tuberculous meningitis than did either Xpert or culture. WHO now recommends the use of Xpert Ultra as the initial diagnostic test for suspected tuberculous meningitis.

Funding

National Institute of Neurologic Diseases and Stroke, Fogarty International Center, National Institute of Allergy and Infectious Disease, UK Medical Research Council/DfID/Wellcome Trust Global Health Trials, Doris Duke Charitable Foundation.

Le texte complet de cet article est disponible en PDF.

Plan


© 2018  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 18 - N° 1

P. 68-75 - janvier 2018 Retour au numéro
Article précédent Article précédent
  • A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial
  • Sirintip Sricharoenchai, Chukiat Sirivichayakul, Kulkanya Chokephaibulkit, Punnee Pitisuttithum, Jittima Dhitavat, Arom Pitisuthitham, Wanatpreeya Phongsamart, Kobporn Boonnak, Keswadee Lapphra, Yupa Sabmee, Orasri Wittawatmongkol, Pailinrut Chinwangso, Indrajeet Kumar Poredi, Jean Petre, Pham Hong Thai, Simonetta Viviani
| Article suivant Article suivant
  • Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
  • Susan E Dorman, Samuel G Schumacher, David Alland, Pamela Nabeta, Derek T Armstrong, Bonnie King, Sandra L Hall, Soumitesh Chakravorty, Daniela M Cirillo, Nestani Tukvadze, Nino Bablishvili, Wendy Stevens, Lesley Scott, Camilla Rodrigues, Mubin I Kazi, Moses Joloba, Lydia Nakiyingi, Mark P Nicol, Yonas Ghebrekristos, Irene Anyango, Wilfred Murithi, Reynaldo Dietze, Renata Lyrio Peres, Alena Skrahina, Vera Auchynka, Kamal Kishore Chopra, Mahmud Hanif, Xin Liu, Xing Yuan, Catharina C Boehme, Jerrold J Ellner, Claudia M Denkinger, study team, Susan E Dorman, Samuel G Schumacher, David Alland, Pamela Nabeta, Derek T Armstrong, Bonnie King, Sandra L Hall, Soumitesh Chakravorty, Daniela M Cirillo, Nestani Tukvadze, Nino Bablishvili, Wendy Stevens, Lesley Scott, Camilla Rodrigues, Mubin I Kazi, Moses Joloba, Lydia Nakiyingi, Mark P Nicol, Yonas Ghebrekristos, Irene Anyango, Wilfred Murithi, Reynaldo Dietze, Renata Lyrio Peres, Alena Skrahina, Vera Auchynka, Kamal Kishore Chopra, Mahmud Hanif, Xin Liu, Xing Yuan, Catharina C Boehme, Jerrold J Ellner, Claudia M Denkinger, Yukari C Manabe, David Hom, Rusudan Aspindzelashvili, Anura David, Utkarsha Surve, Louis Henry Kamulegeya, Sheila Nabweyambo, Shireen Surtie, Nchimunya Hapeela, Kevin P Cain, Janet Agaya, Kimberly D McCarthy, Patricia Marques-Rodrigues, Luiz Guilherme Schmidt Castellani, Pedro Sousa Almeida, Paola Poloni Lobo de Aguiar, Varvara Solodovnikova, Xianglin Ruan, Lili Liang, Guolong Zhang, Hong Zhu, Yingda Xie

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.